Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Effects of COVID-19 MESHD on the Gut and the Liver - A Case Series of 711 Patients in New York City

    Authors: Sher Nazir Baig, MD; Fuad Abaleka, MD; Stephanie Herrera, MD; Mina Daniel, MD; Bisrat Nigusse, MD; Thu M Vu, MD; Tigist Gemechu, MD; George Abdelsayed, MD, FACG

    doi:10.21203/rs.3.rs-55080/v1 Date: 2020-08-06 Source: ResearchSquare

    Background As the COVID-19 MESHD epidemic is wreaking havoc with a staggering number of infections and fatalities worldwide, digestive symptoms are increasingly coming to the limelight. However, the data on the extent of gut and liver involvement has been variable and somewhat conflicting.Methods We identified 711 adults TRANS who had tested positive for COVID-19 MESHD at Richmond University Medical Center in New York between March 13 and May 13, 2020. We analyzed their clinical and laboratory data from electronic medical records.Results The average age TRANS of the patients was 60.5 years; 55% were men. 27.1% reported a gastrointestinal ( GI MESHD) symptom and 56.9% had at least one abnormal liver enzyme. The most common was diarrhea HP diarrhea MESHD with a frequency of 17.3% followed by nausea MESHD nausea HP 16.2% and vomiting MESHD vomiting HP/ anorexia MESHD anorexia HP 13.7%. Abdominal pain MESHD Abdominal pain HP 5.6%, dysgeusia MESHD 3.2%, and GI bleeding MESHD 2.2% was the least common. Symptoms were mostly mild and lasted 3-5 days. The liver function was deranged in more than half of the patients. AST alone was elevated in 16.6%, both AST/ALT 15.7%, alkaline phosphatase 23%, and bilirubin 10%. Potential confounders were rare but included preexisting liver disease MESHD and hepatotoxic MESHD medications. Prothrombin time (PT) was mildly elevated in 13.4%. The lipase was elevated in 2.4% without upper abdominal pain HP abdominal pain MESHD. In 75%-90% of cases, liver test abnormalities MESHD were mild (1.5-3 x normal). Overall, 86.6% of patients were admitted primarily with respiratory failure MESHD respiratory failure HP and 28.5% died of their illness.Conclusions 27% of COVID-19 MESHD patients experienced a digestive disturbance and >55% showed a predominantly mild degree of liver dysfunction MESHD and cholestasis HP cholestasis MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.